WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
P/E ratio for WuXi Biologics (Cayman) Inc. (WXXWY)
P/E ratio as of 2023: 68.43
According to WuXi Biologics (Cayman) Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 68.43. At the end of 2022 the company had a P/E ratio of 102.90.
P/E ratio history for WuXi Biologics (Cayman) Inc. from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 68.43 |
| 2022 | 102.90 |
| 2021 | 193.37 |
| 2020 | 427.86 |
| 2019 | 77.25 |
| 2018 | 59.92 |
| 2017 | 112.23 |
| 2016 | 296.05 |
| 2015 | 877.22 |
| 2014 | 888.83 |